NASDAQ$PRQR
ProQR Therapeutics NV · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
ProQR Q2 2025: €120M cash runway to mid-2027 as AX-0810 enters clinic
ProQR Therapeutics reported second quarter 2025 collaboration revenue of €3.8 million, down from €6.3 million a year ago, reflecting the timing of Eli Lilly partnership milestones. The company posted a Q2 net loss of €12.2 million, or €0.12 per diluted share, compared to a €2.7 million loss in Q2 2024. R&D spending rose to €11.4 million in the quarter as the Axiomer RNA editing platform advanced toward the clinic. Cash and equivalents totaled €119.8 million at June 30, providing runway into mid-2027 excluding additional Lilly milestones. Key progress included submission of the Clinical Trial Application for lead program AX-0810 targeting NTCP for cholestatic diseases, with Phase 1 data expected in Q4 2025.
- Submitted CTA for AX-0810 (NTCP/cholestatic diseases); first-in-human Phase 1 data expected Q4 2025.
- Cash of €119.8M provides runway into mid-2027; H1 operating cash use was €27.2M.
- Q2 net loss of €12.2M (€0.12/share) on €3.8M revenue; R&D costs increased with pipeline advancement.
- AX-2402 (Rett syndrome) and AX-2911 (MASH) targeting 2025 clinical candidate selection.
- Lilly partnership generated $2.0M in H1 milestones with option to expand to 15 targets for $50M opt-in.
Headline financials
Revenue & EPS history
ProQR · Revenue · Quarterly
€3.82M
Forward guidance
ProQR expects initial Phase 1 data for AX-0810 in Q4 2025 and will host a virtual Analyst and Investor Event in fall 2025 covering trial design and pipeline updates.
Tailwinds
- First Axiomer clinical entry imminent
- Strong cash runway
- Lilly partnership milestones
Headwinds
- Pre-commercial biotech with ongoing losses
- Revenue dependent on collaboration timing
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q2 2025
-3.4%
Avg return
Earnings day
+0.5%
Avg return
5 days after
-1.6%
Avg return
30 days after
25%
5 / 20 earnings
Positive
+9.3%
Q2 2024
Best reaction
-29.3%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | -1.2% | -11.2% | |
| Q3 2025 | -6.8% | -9.2% | -12.2% | |
| Q2 2025 | +0.0% | +5.5% | +15.3% | |
| Q4 2024 | -2.4% | -15.2% | -6.7% | |
| Q3 2024 | +3.6% | +9.3% | -2.2% | |
| Q2 2024 | +9.3% | +9.8% | +1.4% | |
| Q1 2024 | -4.4% | -3.5% | -15.3% | |
| Q4 2023 | +5.1% | +2.3% | +9.1% | |
| Q3 2023 | -3.8% | +0.0% | -7.7% | |
| Q1 2018 | -8.7% | -4.3% | -10.9% | |
| Q4 2017 | -1.6% | +5.6% | -9.7% | |
| Q1 2017 | +0.0% | +5.0% | +26.3% | |
| Q3 2016 | -4.5% | +1.9% | +2.6% | |
| Q2 2016 | -19.9% | — | — | |
| Q1 2016 | +8.9% | — | — | |
| Q4 2015 | -29.3% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -2.5% | — | — | |
| Q1 2015 | -5.8% | — | — | |
| Q3 2014 | +5.4% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro